Spyre Therapeutics (SYRE) Payables (2015 - 2026)

Spyre Therapeutics' Payables history runs 12 years deep, the most recent figure standing at $56.0 million for Q1 2026.

• Quarterly Payables rose 20.33% year-over-year to $56.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.0 million (up 20.33% YoY) and the FY2025 annual result came in at $31.7 million, up 23.22% from the prior year.
• Payables was $56.0 million for Q1 2026 at Spyre Therapeutics, up from $31.7 million in the prior quarter.
• Across five years, Payables topped out at $63.6 million in Q2 2025 and bottomed at $2.0 million in Q2 2022.
• A 5-year average of $20.6 million and a median of $13.8 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables jumped 1108.58% — and 2024, when it tumbled 75.19%.
• Spyre Therapeutics' Payables stood at $4.2 million in 2022, then plunged by 45.28% to $2.3 million in 2023, then jumped by 1026.25% to $25.7 million in 2024, then climbed by 23.22% to $31.7 million in 2025, then jumped by 76.37% to $56.0 million in 2026.
• Business Quant data shows SYRE's Payables at $56.0 million in Q1 2026, $31.7 million in Q4 2025, and $18.5 million in Q3 2025.